Citius Pharmaceuticals, Inc.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2013
- $0
- Net income
- -$32.5M
- Total assets
- $130.9M
- Market cap
- $15.4M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $38.5M
- Operating income
- -$38.5M
- Income tax
- $1.1M
- Net income
- -$39.7M
- EPS (basic)
- $-3.38
- EPS (diluted)
- $-3.38
Balance sheet
- Total assets
- $130.9M
- Current assets
- $27.9M
- Total liabilities
- $53.4M
- Current liabilities
- $44.9M
- Shareholders’ equity
- $77.5M
Cash flow
- Operating cash flow
- -$26.6M
- Investing cash flow
- -$5.8M
- Financing cash flow
- $33.3M
- Net cash flow
- $1.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $15.4M
- EPS (diluted)
- $-3.38
- Shares outstanding
- 26.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 18, 2011
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $32.5M in FY2013.
- Trading 73% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Citius Pharmaceuticals, Inc..
Write a review
News about Citius Pharmaceuticals, Inc.
News & sentiment via Polygon.io
